Hope Renewed: Ultragenyx Resubmits Landmark Gene Therapy for Fatal Childhood Disease

NOVATO, CA – January 30, 2026 – In a move that has reignited hope for thousands of families worldwide, Ultragenyx Pharmaceutical Inc. announced today it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for UX111, a pioneering gene therapy for the fatal childhood disease Sanfilippo syndrome type A (MPS IIIA).

The resubmission marks a critical step in a long and arduous journey for a potential first-ever treatment for this relentlessly progressive neurodegenerative disorder. It comes just over six months after the company received a Complete Response Letter (CRL) from the FDA, a setback that temporarily delayed the therapy's path to market but did not diminish the company's resolve.

“Today, with no approved treatment options to address the relentless progression of Sanfilippo syndrome type A, families must watch helplessly as their children lose the ability to communicate, play, move, and even eat before ultimately succumbing to this devastating and fatal disease,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx, in a statement. “We recognize the extraordinary stakes facing the Sanfilippo community as they await a first-ever treatment option and look forward to working with the Agency as it completes its review of this urgently needed therapy.”

The Devastation of Sanfilippo Syndrome

Sanfilippo syndrome type A is a rare lysosomal storage disease that is both cruel and swift. Affecting an estimated 3,000 to 5,000 patients in commercially accessible regions, the disease is caused by a genetic mutation that prevents the body from producing a critical enzyme, sulfamidase (SGSH). Without this enzyme, a complex sugar molecule called heparan sulfate accumulates in cells, particularly in the brain, leading to catastrophic and irreversible damage.

Children born with MPS IIIA often appear healthy at first, but developmental delays typically emerge in early childhood. What follows is a heartbreaking regression. Toddlers who had begun to speak lose their words. Children who learned to run lose their motor skills. The progressive cognitive decline is often accompanied by severe behavioral issues, sleep disturbances, and seizures. With no approved therapies to halt or slow this process, current care is purely supportive, focused on managing symptoms as children lose their acquired abilities. The median life expectancy is just 15 years.

For families, a diagnosis is a devastating blow, initiating a race against time for a disease with no cure and a grim, predictable trajectory. The profound unmet medical need has made the development of a disease-modifying therapy a paramount goal for researchers and patient advocates alike.

Navigating the Regulatory Labyrinth

Ultragenyx's path to approval highlights the immense challenges of bringing a complex gene therapy for a rare disease to market. The company's initial BLA for UX111 was granted Priority Review by the FDA in February 2025, signaling the agency's recognition of its potential to address a serious condition. However, in July 2025, the FDA issued a Complete Response Letter.

Importantly, the CRL did not raise new concerns about the clinical data's robustness or the therapy's safety profile. Instead, it focused on Chemistry, Manufacturing, and Controls (CMC) observations related to production processes and facility inspections. Ultragenyx has since worked to meticulously address every point raised by the agency.

The resubmitted BLA not only contains comprehensive responses to the CMC issues but also includes additional, longer-term clinical data, as requested by the FDA. This new data, representing up to 8.5 years of follow-up for some patients, reportedly shows a durable treatment effect, further separating the clinical outcomes of treated patients from the disease's natural history and reinforcing the therapy's long-term safety.

The Science of a Single-Dose Solution

UX111, also known as rebisufligene etisparvovec, is a novel in vivo gene therapy designed to address the root cause of MPS IIIA. It is administered as a one-time intravenous infusion. The therapy uses a modified, harmless adeno-associated virus (AAV9) as a delivery vehicle to carry a functional copy of the SGSH gene to cells throughout the body, including the brain.

Once delivered, the new gene enables cells to produce the missing SGSH enzyme. This functional enzyme can then break down the toxic accumulation of heparan sulfate, aiming to prevent the progressive cellular damage that drives the neurodegeneration. The application seeks accelerated approval, a pathway used for drugs treating serious conditions with an unmet need, based on a surrogate endpoint—in this case, the reduction of heparan sulfate in the cerebrospinal fluid, which is considered a strong indicator of clinical benefit in the brain.

A Defining Moment for Ultragenyx and Rare Disease

If approved, UX111 would be a landmark achievement, becoming the first-ever therapy for Sanfilippo syndrome type A and validating Ultragenyx’s strategy of tackling rare and ultra-rare diseases. The approval would provide a significant commercial opportunity for the company, establishing it as the leader in a market with no competition.

For the broader biotech industry, the successful navigation of UX111's regulatory challenges could provide a valuable roadmap for future gene therapy development. The company's persistence in generating long-term follow-up data to satisfy regulatory requirements underscores the high bar for these revolutionary treatments.

With the BLA now resubmitted, the clock starts again. Ultragenyx anticipates up to a six-month review period, which would place a potential FDA decision and a Prescription Drug User Fee Act (PDUFA) action date in the third quarter of 2026. For the thousands of families in the Sanfilippo community, this timeline represents a new window of hope as they anxiously await a final decision on this potentially life-altering therapy.